OTOF-GT (SENS-501)
Otoferlin Deficiency (Auditory Neuropathy)
Phase 1/2Active
Key Facts
About Sensorion
Sensorion's mission is to address the profound unmet medical need in hearing loss through a three-pillar strategy: Restore hearing via gene therapy for genetic disorders, Treat acute hearing loss with small molecules, and Prevent hearing loss in various settings. The company has established a proprietary R&D platform and advanced its lead gene therapy candidate, OTOF-GT, into a Phase 1/2 trial for otoferlin deficiency. Its strategy combines internal development with strategic partnerships to build a comprehensive portfolio targeting both rare and common forms of auditory impairment.
View full company profile